Induction of myelo-monocytic My7 antigen (CD13) expression by interferon-α in basal cells of cutaneous T-cell lymphomas
- 1 April 1992
- journal article
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 126 (4), 320-323
- https://doi.org/10.1111/j.1365-2133.1992.tb00672.x
Abstract
The My7 antigen that is expressed on the basal cells in normal skin and inflammatory disorders is absent in the lesions of cutaneous T-cell lymphoma (CTCL). Induction of My7 expression in basal cells in the cutaneous lesions of 12 patients with mycosis fungoides and three with Sézary syndrome treated with interferon-alpha 2a (IFN-alpha 2a) for 10 months was investigated. Biopsies were taken from the same area before treatment and after 2, 6 and 10 months of therapy with IFN-alpha 2a. My7 antigen was expressed on the basal cells only in those patients who showed either a complete or partial response to therapy with IFN-alpha 2a.Keywords
This publication has 7 references indexed in Scilit:
- MY7 monoclonal antibody for diagnosis of cutaneous T-cell lymphomaArchives of Dermatology, 1990
- Effect of interferon-alpha on the expression and release of the CD23 molecule in hairy cell leukemiaBlood, 1989
- Low-dose recombinant interferon-α in the treatment of cutaneous T-cell lympbomasBritish Journal of Dermatology, 1989
- Interferon alfa-2a in the treatment of cutaneous T cell lymphomaJournal of the American Academy of Dermatology, 1989
- Low dosage alpha‐interferon treatment in patients with advanced cutaneous T‐cell lymphomaEuropean Journal of Haematology, 1988
- The role of recombinant interferon alfa-2a in the therapy of cutaneous t-cell lymphomasCancer, 1986
- Expression of myeloid differentiation antigens on normal and malignant myeloid cells.JCI Insight, 1981